Vyome Reports Q1 2026 Results; In-licenses JAK Inhibitors, Files VT-1953 Orphan Drug Application

Vyome Holdings signed an agreement with Impetis Biosciences to in-license two JAK inhibitor assets targeting a $57B market and submitted an FDA Orphan Drug Designation application for VT-1953 in malignant fungating wounds. The company ended Q1 2026 with $8.8 million in cash and no debt, positioning itself for continued clinical advancement while maintaining financial discipline.